FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029508965> ?p ?o ?g. }

• W3029508965 endingPage "936" @default.
• W3029508965 startingPage "931" @default.
• W3029508965 abstract "Background We investigated the treatment outcomes before and after the addition of amikacin to cefepime monotherapy as an initial empirical antibiotic treatment in pediatric cancer patients with febrile neutropenia. Methods This was a retrospective historical cohort study. The subjects were pediatric cancer patients who visited the emergency room at the Samsung Medical Center, Seoul, Korea, due to chemotherapy-induced febrile neutropenia, between January 2011 and December 2016. Since September 2014, the empirical antimicrobial treatment regimen for febrile neutropenia was changed from high-dose cefepime monotherapy to combination therapy of adding a single dose of amikacin. Results Two hundred twenty-five bacteremia episodes in 164 patients were reported during the study period. Bacteremia caused by cefepime-resistant Gram-negative bacteria was observed in 16% of patients before September 2014 and in 21% of the patients after September 2014 (P = 0.331). Use of appropriate empirical antibiotic treatments increased from 62% to 83% following addition of amikacin to cefepime treatment (P = 0.003). The duration of fever was shorter in the cefepime plus amikacin group than in the cefepime group (22 vs. 34 hours, P = 0.014); however, rates of septic shock and pediatric intensive care unit hospitalizations were not significantly different between the 2 groups (septic shock, both 7%, P = 0.436; pediatric intensive care unit 3% vs. 1%, P = 0.647). Conclusions We observed no additional benefit of amikacin addition to high-dose cefepime monotherapy. Therefore, adding amikacin to cefepime monotherapy in conditions where cefepime-resistant Gram-negative bacteremia amounts to 20% or less may not be justified." @default.
• W3029508965 created "2020-06-05" @default.
• W3029508965 creator A5010572665 @default.
• W3029508965 creator A5023794901 @default.
• W3029508965 creator A5032339139 @default.
• W3029508965 creator A5038057658 @default.
• W3029508965 creator A5038480858 @default.
• W3029508965 creator A5038682278 @default.
• W3029508965 creator A5065602761 @default.
• W3029508965 creator A5068266757 @default.
• W3029508965 creator A5082079750 @default.
• W3029508965 date "2020-05-21" @default.
• W3029508965 modified "2023-10-18" @default.
• W3029508965 title "Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance" @default.
• W3029508965 cites W1414307846 @default.
• W3029508965 cites W1857700311 @default.
• W3029508965 cites W1967300023 @default.
• W3029508965 cites W1976058052 @default.
• W3029508965 cites W1999059251 @default.
• W3029508965 cites W2015629749 @default.
• W3029508965 cites W2018136144 @default.
• W3029508965 cites W2028056979 @default.
• W3029508965 cites W2032000730 @default.
• W3029508965 cites W2035884979 @default.
• W3029508965 cites W2048049852 @default.
• W3029508965 cites W2054544213 @default.
• W3029508965 cites W2061194988 @default.
• W3029508965 cites W2083022489 @default.
• W3029508965 cites W2085514679 @default.
• W3029508965 cites W2096598041 @default.
• W3029508965 cites W2098228819 @default.
• W3029508965 cites W2098357010 @default.
• W3029508965 cites W2104541470 @default.
• W3029508965 cites W2118102004 @default.
• W3029508965 cites W2120417371 @default.
• W3029508965 cites W2122335736 @default.
• W3029508965 cites W2124354104 @default.
• W3029508965 cites W2124888195 @default.
• W3029508965 cites W2130643548 @default.
• W3029508965 cites W2145136986 @default.
• W3029508965 cites W2160971726 @default.
• W3029508965 cites W2162823164 @default.
• W3029508965 cites W2166895354 @default.
• W3029508965 cites W2171285717 @default.
• W3029508965 cites W2529736552 @default.
• W3029508965 cites W2610889635 @default.
• W3029508965 cites W2619844151 @default.
• W3029508965 cites W2803662409 @default.
• W3029508965 cites W3022798003 @default.
• W3029508965 cites W648821351 @default.
• W3029508965 doi "https://doi.org/10.1097/inf.0000000000002751" @default.
• W3029508965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32453199" @default.
• W3029508965 hasPublicationYear "2020" @default.
• W3029508965 type Work @default.
• W3029508965 sameAs 3029508965 @default.
• W3029508965 citedByCount "4" @default.
• W3029508965 countsByYear W30295089652020 @default.
• W3029508965 countsByYear W30295089652021 @default.
• W3029508965 countsByYear W30295089652022 @default.
• W3029508965 countsByYear W30295089652023 @default.
• W3029508965 crossrefType "journal-article" @default.
• W3029508965 hasAuthorship W3029508965A5010572665 @default.
• W3029508965 hasAuthorship W3029508965A5023794901 @default.
• W3029508965 hasAuthorship W3029508965A5032339139 @default.
• W3029508965 hasAuthorship W3029508965A5038057658 @default.
• W3029508965 hasAuthorship W3029508965A5038480858 @default.
• W3029508965 hasAuthorship W3029508965A5038682278 @default.
• W3029508965 hasAuthorship W3029508965A5065602761 @default.
• W3029508965 hasAuthorship W3029508965A5068266757 @default.
• W3029508965 hasAuthorship W3029508965A5082079750 @default.
• W3029508965 hasConcept C121608353 @default.
• W3029508965 hasConcept C126322002 @default.
• W3029508965 hasConcept C167135981 @default.
• W3029508965 hasConcept C2776694085 @default.
• W3029508965 hasConcept C2777050379 @default.
• W3029508965 hasConcept C2777063308 @default.
• W3029508965 hasConcept C2777427914 @default.
• W3029508965 hasConcept C2777628635 @default.
• W3029508965 hasConcept C2778384902 @default.
• W3029508965 hasConcept C2778850193 @default.
• W3029508965 hasConcept C2779443120 @default.
• W3029508965 hasConcept C2779631663 @default.
• W3029508965 hasConcept C2993561819 @default.
• W3029508965 hasConcept C501593827 @default.
• W3029508965 hasConcept C71924100 @default.
• W3029508965 hasConcept C86803240 @default.
• W3029508965 hasConcept C89423630 @default.
• W3029508965 hasConcept C94665300 @default.
• W3029508965 hasConceptScore W3029508965C121608353 @default.
• W3029508965 hasConceptScore W3029508965C126322002 @default.
• W3029508965 hasConceptScore W3029508965C167135981 @default.
• W3029508965 hasConceptScore W3029508965C2776694085 @default.
• W3029508965 hasConceptScore W3029508965C2777050379 @default.
• W3029508965 hasConceptScore W3029508965C2777063308 @default.
• W3029508965 hasConceptScore W3029508965C2777427914 @default.
• W3029508965 hasConceptScore W3029508965C2777628635 @default.
• W3029508965 hasConceptScore W3029508965C2778384902 @default.
• W3029508965 hasConceptScore W3029508965C2778850193 @default.

• next